David Lebowitz
Stock Analyst at BMO Capital
(4.75)
# 653
Out of 4,996 analysts
476
Total ratings
58.7%
Success rate
13.8%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintained: Hold | $54 | $46.75 | +15.51% | 53 | Sep 24, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $318 | $245.51 | +29.53% | 58 | Sep 18, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $98 → $97 | $65.08 | +49.05% | 24 | Sep 16, 2026 | |
| ASND Ascendis Pharma | Reiterated: Buy | $319 | $239.04 | +33.45% | 41 | Sep 14, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $11 | $2.88 | +281.94% | 2 | Sep 14, 2026 | |
| EXEL Exelixis | Reiterated: Hold | $54 | $58.49 | -7.68% | 19 | Sep 11, 2026 | |
| PRME Prime Medicine | Initiated Coverage: Buy | $9 | $3.14 | +186.62% | 1 | Aug 19, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $37 | $22.86 | +61.85% | 1 | Aug 18, 2026 | |
| BCAX Bicara Therapeutics | Initiated Coverage: Buy | $35 | $22.59 | +54.94% | 1 | Aug 18, 2026 | |
| COGT Cogent Biosciences | Reiterated: Buy | $22 | $33.19 | n/a | 13 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $17 | $67.74 | n/a | 17 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $77 → $84 | $69.92 | n/a | 6 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $67 | $67.31 | n/a | 21 | Sep 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $48 | $38.98 | n/a | 5 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $38 → $29 | $29.36 | n/a | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $505 | $534.40 | n/a | 14 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $72 → $89 | $98.82 | n/a | 22 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $35 → $20 | $30.24 | n/a | 22 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1.7 | $1.13 | n/a | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $12 | $12.26 | n/a | 19 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 → $103 | $127.62 | n/a | 21 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $32 → $45 | $68.00 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2.75 | $0.8955 | n/a | 5 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $12 → $14 | $4.23 | n/a | 15 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $27 | $1.79 | n/a | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $21 | $17.68 | n/a | 13 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 → $25 | $27.21 | n/a | 8 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $39 | $4.46 | n/a | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 → $54 | $99.02 | n/a | 11 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $50 | $26.46 | n/a | 2 | Jul 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $15 → $17 | $4.13 | n/a | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $0.0001 | n/a | 3 | Dec 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $60 | $20.67 | n/a | 1 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $126 | $516.34 | n/a | 1 | Jan 9, 2015 |
Ionis Pharmaceuticals
Sep 24, 2026
Maintained: Hold
Price Target: $54
Current: $46.75
Upside: +15.51%
Alnylam Pharmaceuticals
Sep 18, 2026
Maintained: Buy
Price Target: $318
Current: $245.51
Upside: +29.53%
BioMarin Pharmaceutical
Sep 16, 2026
Rated: Buy
Price Target: $98 → $97
Current: $65.08
Upside: +49.05%
Ascendis Pharma
Sep 14, 2026
Reiterated: Buy
Price Target: $319
Current: $239.04
Upside: +33.45%
Perspective Therapeutics
Sep 14, 2026
Reiterated: Buy
Price Target: $11
Current: $2.88
Upside: +281.94%
Exelixis
Sep 11, 2026
Reiterated: Hold
Price Target: $54
Current: $58.49
Upside: -7.68%
Prime Medicine
Aug 19, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.14
Upside: +186.62%
Aktis Oncology
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $37
Current: $22.86
Upside: +61.85%
Bicara Therapeutics
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $22.59
Upside: +54.94%
Cogent Biosciences
Sep 4, 2025
Reiterated: Buy
Price Target: $22
Current: $33.19
Upside: n/a
Sep 3, 2025
Reiterated: Hold
Price Target: $17
Current: $67.74
Upside: n/a
Sep 3, 2025
Reiterated: Buy
Price Target: $77 → $84
Current: $69.92
Upside: n/a
Sep 1, 2025
Reiterated: Buy
Price Target: $67
Current: $67.31
Upside: n/a
Aug 20, 2025
Reiterated: Buy
Price Target: $70 → $48
Current: $38.98
Upside: n/a
Aug 20, 2025
Reiterated: Hold
Price Target: $38 → $29
Current: $29.36
Upside: n/a
Aug 19, 2025
Rated: Buy
Price Target: $505
Current: $534.40
Upside: n/a
Aug 18, 2025
Reiterated: Buy
Price Target: $72 → $89
Current: $98.82
Upside: n/a
Aug 15, 2025
Downgraded: Hold
Price Target: $35 → $20
Current: $30.24
Upside: n/a
Aug 11, 2025
Reiterated: Hold
Price Target: $1.5 → $1.7
Current: $1.13
Upside: n/a
Aug 8, 2025
Reiterated: Hold
Price Target: $10 → $12
Current: $12.26
Upside: n/a
Jul 30, 2025
Reiterated: Buy
Price Target: $88 → $103
Current: $127.62
Upside: n/a
Feb 11, 2025
Reiterated: Sell
Price Target: $32 → $45
Current: $68.00
Upside: n/a
Nov 5, 2021
Reiterated: Hold
Price Target: $3 → $2.75
Current: $0.8955
Upside: n/a
Oct 12, 2021
Reiterated: Hold
Price Target: $12 → $14
Current: $4.23
Upside: n/a
Oct 12, 2021
Reiterated: Buy
Price Target: $29 → $27
Current: $1.79
Upside: n/a
Oct 12, 2021
Reiterated: Hold
Price Target: $20 → $21
Current: $17.68
Upside: n/a
Oct 12, 2021
Reiterated: Buy
Price Target: $29 → $25
Current: $27.21
Upside: n/a
Aug 24, 2021
Initiated Coverage: Hold
Price Target: $39
Current: $4.46
Upside: n/a
Aug 3, 2021
Reiterated: Buy
Price Target: $57 → $54
Current: $99.02
Upside: n/a
Jul 16, 2021
Reiterated: Buy
Price Target: $52 → $50
Current: $26.46
Upside: n/a
Apr 30, 2021
Reiterated: Sell
Price Target: $15 → $17
Current: $4.13
Upside: n/a
Dec 7, 2020
Reiterated: Hold
Price Target: $20
Current: $0.0001
Upside: n/a
Oct 2, 2017
Upgraded: Buy
Price Target: $60
Current: $20.67
Upside: n/a
Jan 9, 2015
Initiated Coverage: Hold
Price Target: $126
Current: $516.34
Upside: n/a